Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Liabilities
Everything the company owes to creditors and other parties.
Entera Bio Ltd.NASDAQ: ENTX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 10.0% from a year ago
Total liabilities stood at $2.44M at the end of Q1 FY2026, up 10.0% from a year earlier and down 15.6% from the prior quarter. Over 3 fiscal years it compounded at +28.2% a year.
Context
- Total liabilities amounted to 18.6% of total assets at the end of Q1 FY2026, up 8.3 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +10.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.89M USD
- Year-over-year change
- +120.8%
- 4-year CAGR
- -4.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.89M | +120.8% |
| FY2024 | 2024-12-31 | 1.31M | -5.0% |
| FY2023 | 2023-12-31 | 1.38M | +0.4% |
| FY2022 | 2022-12-31 | 1.37M | -59.9% |
| FY2021 | 2021-12-31 | 3.42M | — |
Total Liabilities vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total liabilities of $2.44M is the 9th highest of the 10 companies compared; the peer median is $43.71M.
- Its year-over-year change of +10.0% is the 4th highest of 10, against a peer median of -15.5%.
- Total liabilities amounts to 18.6% of total assets for ENTX, versus a peer median of 34.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $414.44M | -20.7% | +2.5% | 222.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $112.62M | +161.3% | +133.2% | 168.6% |
| Mar 2026 | $91.12M | -19.9% | -34.7% | 77.5% | |
| Mar 2026 | $46.15M | -5.7% | +88.6% | 34.5% | |
| Mar 2026 | $43.71M | +21.3% | -26.4% | 87.8% | |
| Mar 2026 | $30.65M | -15.5% | -3.5% | 11.3% | |
| Mar 2026 | $6.51M | +36.2% | +30.4% | 21.9% | |
| Mar 2026 | $6.09M | -86.1% | -41.3% | 10.3% | |
| Mar 2026 | $2.44M | +10.0% | +28.2% | 18.6% | |
| Apr 2026 | $1.64M | -20.8% | -1.3% | 11.0% | |
| Peer median (excluding ENTX) | $43.71M | -15.5% | -1.3% | 34.5% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.